BMO Capital Downgrades Clinical Data (CLDA) to Market Perform
CLDA Hot Sheet
Rating Summary:0 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
BMO Capital downgraded Clinical Data (NASDAQ: CLDA) from Outperform to Market Perform. PT $31.
For more ratings news on Clinical Data click here and for the rating history of Clinical Data click here.
Shares of Clinical Data closed at $30.95 yesterday, with a 52 week range of $10.87-$34.95.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For more ratings news on Clinical Data click here and for the rating history of Clinical Data click here.
Shares of Clinical Data closed at $30.95 yesterday, with a 52 week range of $10.87-$34.95.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
